甲状腺球蛋白和甲状腺球蛋白抗体在分化型甲状腺癌诊治中的应用进展

程少浩; 苏艳军; 程若川

doi:10.3969/j.issn.1000-8179.2020.22.707

甲状腺球蛋白和甲状腺球蛋白抗体在分化型甲状腺癌诊治中的应用进展

doi: 10.3969/j.issn.1000-8179.2020.22.707

昆明医科大学第一附属医院甲状腺疾病诊治中心(昆明市 650032)

基金项目:

国家自然科学基金项目 81760142

详细信息

作者简介:
程少浩专业方向为甲状腺与甲状旁腺外科治疗。E-mail:847271425@qq.com

通讯作者:
苏艳军 suyanjun20042003@aliyun.com

计量
- 文章访问数: 702
- HTML全文浏览量: 102
- PDF下载量: 79
- 被引次数: 0
出版历程
- 收稿日期: 2020-06-17
- 刊出日期: 2020-12-26

Research progress on thyroglobulin and anti-thyroglobulin antibodies in the diagnosis and treatment of differentiated thyroid cancer

Department of Thyroid Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China

Funds:

National Natural Science Foundation of China 81760142

More Information

Corresponding author: Yanjun Su; E-mail: suyanjun20042003@aliyun.com

摘要

摘要: 分化型甲状腺癌（differentiated thyroid cancer，DTC）作为目前发病率上升最快、甲状腺外科最常见的内分泌恶性肿瘤而备受关注。通常选择甲状腺全切或近全切除术，术后配合甲状腺激素替代治疗以及¹³¹I消融治疗。甲状腺球蛋白（thyroglobulin，Tg）作为DTC术后随访的血清学标志物，易受到甲状腺球蛋白抗体（thyroglobulin antibody，TgAb）的干扰。本文着重探讨Tg、TgAb在DTC诊治中的意义，以期为研究提供更多的临床依据。
- 甲状腺球蛋白 /
- 甲状腺球蛋白抗体 /
- 分化型甲状腺癌
Abstract: Differentiated thyroid cancer (DTC) is a malignant endocrine tumor with a rapidly increasing incidence. It is the most common cancer in thyroid surgery and has attracted much attention. Total or near-total thyroidectomy is usually performed, followed by thyroid hormone replacement therapy and ¹³¹I ablation. Thyroglobulin (Tg), a serological marker used in the postoperative follow-up of DTC, is susceptible to interference by thyroglobulin antibody (TgAb). In this review, we will focus on the significance of Tg and TgAb in the diagnosis and treatment of DTC to provide evidence for future clinical studies.
- thyroglobulin (Tg) /
- thyroglobulin antibody (TgAb) /
- differentiated thyroid cancer (DTC)

HTML全文

参考文献(30)

[1] Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables[J]. Clin Oncol (R Coll Radiol), 2010, 22(6):395-404. doi: 10.1016/j.clon.2010.05.004
[2]	Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1):1-133. doi: 10.1089/thy.2015.0020
[3]	Fröhlich E, Wahl R. Thyroid autoimmunity:role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases[J]. Front Immunol, 2017, 9(8):521. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422478/
[4]	Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens[J]. Ann Intern Med, 2003, 139(5 Pt 1):346-351. http://www.ncbi.nlm.nih.gov/pubmed/12965943
[5]	Rinaldi S, Plummer M, Biessy C, et al. Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma:the EPIC study[J]. J Natl Cancer Inst, 2014, 106(6):97.
[6]	Giovanella L. False-negative thyroglobulin measurement in recurrent/metastatic thyroid carcinomas[J]. Eur J Nucl Med Mol Imaging, 2009, 36(2):326-328. doi: 10.1007/s00259-008-1005-9
[7]	Roti E, Robuschi G, Emanuele R, et al. Radioimmunoassay of thyroglobulin in human serum:concentrations in normal subjects and in patients with thyroid disease[J]. J Nucl Med Allied Sci, 1981, 25(3):57-63. http://europepmc.org/abstract/MED/7310527
[8]	高刘艳, 李素平.甲状腺球蛋白和甲状腺球蛋白抗体在分化型甲状腺癌诊治中的价值[J].国际放射医学核医学杂志, 2020, 44(3):196-201. doi: 10.3760/cma.j.cn121381-201812053-00009
[9]	Prpić M, Franceschi M, Romić M, et al. Thyroglobulin as a tumor marker in differentiated thyroid cancer-clinical considerations[J]. Acta Clin Croat, 2018, 57(3):518-527. http://www.ncbi.nlm.nih.gov/pubmed/31168186
[10]	Giovanella L, Clark PM, Chiovato L, et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer:a clinical position paper[J]. Eur J Endocrinol, 2014, 171(2):R33-R46. http://pubmedcentralcanada.ca/pmcc/articles/PMC4076114/
[11]	李田军, 林岩松, 梁军, 等.¹³¹I治疗前刺激性Tg对乳头状甲状腺癌远处转移的预测价值[J].中华核医学与分子影像杂志, 2012, 32(3):189-191. doi: 10.3760/cma.j.issn.2095-2848.2012.03.007
[12]	刘永, 陈鹏, 宋长祥, 等.分化型甲状腺癌术后首次¹³¹I治疗前刺激性Tg水平与转移灶的关系[J].中国临床医学影像杂志, 2017, 28(7):471-474. doi: 10.3969/j.issn.1008-1062.2017.07.004
[13]	李成乾, 王国强, 王叙馥, 等.首次¹³¹I治疗前刺激性Tg对分化型甲状腺癌转移的预测价值[J].中华核医学与分子影像杂志, 2019, 39(7):395-399. doi: 10.3760/cma.j.issn.2095-2848.2019.07.003
[14]	Furuya-Kanamori L, Sedrakyan A, Onitilo AA, et al. Differentiated thyroid cancer:millions spent with no tangible gain[J]? Endocr Relat Cancer, 2018, 25(1):51-57. doi: 10.1530/ERC-17-0397
[15]	McLeod DSA, Cooper DS, Ladenson PW, et al. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis[J]. Thyroid, 2014, 24(1):35-42. doi: 10.1089/thy.2013.0062
[16]	Phan HT, Jager PL, van der Wal JE, et al. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation[J]. Eur J Endocrinol, 2008, 158(1):77-83. doi: 10.1530/EJE-07-0399
[17]	李夏黎, 武新宇, 闫新慧, 等.激发态甲状腺球蛋白评估分化型甲状腺癌¹³¹I清甲治疗后转移的临床价值[J].中华核医学与分子影像杂志, 2017, 37(3):153-156. doi: 10.3760/cma.j.issn.2095-2848.2017.03.007
[18]	张丹凤, 刘学公.血清学标志物在分化型甲状腺癌治疗中的临床价值研究进展[J].中国肿瘤外科杂志, 2019, 11(5):377-380. doi: 10.3969/j.issn.1674-4136.2019.05.018
[19]	Spencer CA. Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)[J]. J Clin Endocrinol Metab, 2011, 96(12):3615-3627. doi: 10.1210/jc.2011-1740
[20]	Kim ES, Lim DJ, Baek KH, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules[J]. Thyroid, 2010, 20(8):885-891. doi: 10.1089/thy.2009.0384
[21]	Qin J, Yu Z, Guan H, et al. High thyroglobulin antibody levels increase the risk of differentiated thyroid carcinoma[J]. Dis Markers, 2015, 2015:648670. http://www.ncbi.nlm.nih.gov/pubmed/26600670
[22]	Hosseini S, Payne RJ, Zawawi F, et al. Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer[J]? J Otolaryngol Head Neck Surg, 2016, 45(1):31. doi: 10.1186/s40463-016-0143-5
[23]	Xu W, Huo L, Chen Z, et al. The relationship of TPOAb and TGAb with risk of thyroid nodules:a large epidemiological study[J]. Int J Environ Res Public Health, 2017, 14(7):723. doi: 10.3390/ijerph14070723
[24]	Grani G, Calvanese A, Carbotta G, et al. Thyroid autoimmunity and risk of malignancy in thyroid nodules submitted to fine-needle aspiration cytology[J]. Head Neck, 2015, 37(2):260-264. doi: 10.1002/hed.23587
[25]	Matrone A, Latrofa F, Torregrossa L, et al. Changing trend of thyroglobulin antibodies in patients with differentiated thyroid cancer treated with total thyroidectomy without ¹³¹I ablation[J]. Thyroid, 2018, 28(7):871-879. doi: 10.1089/thy.2018.0080
[26]	Kim WG, Yoon JH, Kim WB, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 2008, 93(12):4683-4689. doi: 10.1210/jc.2008-0962
[27]	de Meer SGA, Vorselaars W MCM, Kist JW, et al. Follow-up of patients with thyroglobulin-antibodies:Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer[J]. Endocr Res, 2017, 42(4):302-310. doi: 10.1080/07435800.2017.1319858
[28]	Lee ZJO, Eslick GD, Edirimanne S. Investigating anti-thyroglobulin antibody as a prognostic marker for differentiated thyroid cancer:A Meta-Analysis and Systematic Review[J]. Thyroid, 2020.[Online ahead of print.] http://www.researchgate.net/publication/341095992_Investigating_Anti-Thyroglobulin_Antibody_as_a_Prognostic_Marker_for_Differentiated_Thyroid_Cancer_A_Meta-Analysis_and_Systematic_Review
[29]	Ritter A, Mizrachi A, Bachar G, et al. Detecting recurrence following lobectomy for thyroid cancer:role of thyroglobulin and thyroglobulin antibodies[J]. J Clin Endocrinol Metab, 2020, 105(6):152. http://www.researchgate.net/publication/340235564_Detecting_Recurrence_Following_Lobectomy_for_Thyroid_Cancer_Role_of_Thyroglobulin_and_Thyroglobulin_Antibodies
[30]	Li YR, Tseng CP, Hsu HL, et al. Circulating epithelial cells as potential biomarkers for detection of recurrence in patients of papillary thyroid carcinoma with positive serum anti-thyroglobulin antibody[J]. Clin Chim Acta, 2018, 477:74-80. doi: 10.1016/j.cca.2017.12.011